Key statistics
As of last trade, Editas Medicine Inc (8EM:DUS) traded at 2.91, 13.86% above the 52 week low of 2.55 set on Nov 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.87 |
---|---|
High | 2.91 |
Low | 2.87 |
Bid | 2.96 |
Offer | 3.01 |
Previous close | 2.92 |
Average volume | 602.14 |
---|---|
Shares outstanding | 82.55m |
Free float | 82.28m |
P/E (TTM) | -- |
Market cap | 257.55m USD |
EPS (TTM) | -2.56 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 11:31 GMT.
More ▼
Announcements
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Announces Third Quarter 2024 Results and Business Updates
- Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
- Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
- Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
- Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
- Editas Medicine Announces Second Quarter 2024 Results and Business Updates
- Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
- Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
- Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
More ▼